Kindeva Global Health Security Donates ATNAA to Ukraine Through the European Commission's rescEU and Governmental Strategic Reserves Agency (RARS)
29.5.2024 15:00:00 EEST | Business Wire | Press release
Kindeva Drug Delivery (Kindeva), a leading global health security provider of CBRN medical countermeasures, announced that it donated a supply of autoinjectors — specifically an antidotal treatment for chemical nerve agents — to Ukraine through the rescEU reserve of the EU Civil Protection Mechanism to aid civilians affected by the war in Ukraine.1 Medical countermeasures (MCMs), such as the ATNAA (Antidote Treatment Nerve Agent Autoinjector), are instrumental in protecting the lives of civilians and military in the event of a chemical nerve agent attack.
This donation was coordinated with the European Commission, which in 2022, established an operational system under the EU Civil Protection Mechanism to channel in-kind donations from the private sector to Ukraine, Moldova, and neighboring EU countries. Via the EU Civil Protection Mechanism, the EU coordinates emergency supply items, therapeutics and medicines, medical devices, shelter items, and more from private and public companies and entities and non-EU governmental institutions that become part of the rescEU reserve to offer an additional layer of protection when disasters strike. The Governmental Strategic Reserves Agency (RARS) in Poland acts on behalf of the European Commission and rescEU to receive the donation and arrange for local transport to Ukraine.
“The rescEU reserve allows the EU to respond more quickly to medical needs caused by health crises, like the war in Ukraine,” said Kindeva’s Tom Handel, Commercial Head - Injectables & Health Security. “Meridian Medical Technologies (Meridian), which merged with Kindeva Drug Delivery in December 2022 to create a leading drug-device CDMO, is the global health security business unit of Kindeva. The company has been putting emergency care treatment options into the hands of military and civilian defenders for more than 60 years and will continue to do so as a combined organization. Kindeva is pleased we were able to work with the European Commission to donate our chemical nerve agent antidote autoinjectors to boost Ukraine’s CBRN stockpile.”
For more information about what items can be donated, visit European Civil Protection and Humanitarian Aid Operations.
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary & nasal, injectable, and transdermal. Our service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.
1 The delivered goods are meant for emergency aid to Ukraine and are not intended for commercial use in the EU.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529437096/en/
Contact information
Holli Kroeker
+1 308-338-2358
pr@scorrmarketing.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice and NXP Deliver Flexible, Secure Computing Solution for the Industrial Edge10.11.2026 23:00:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced the Lattice NXP PCIe® Companion solution, jointly enabled and promoted with NXP® Semiconductors. Pairing NXP’s i.MX 95 applications processor with Lattice Nexus™-based FPGAs over PCIe, the solution addresses the real-time connectivity, deterministic I/O, and security challenges in industrial automation, robotics, and intelligent edge applications. The joint solution is available in Lattice CertusPro™-NX or Lattice Certus™-NX configurations as companion chips to NXP i.MX 95 SoC compute processors, deepening a long-standing collaboration between Lattice and NXP spanning industrial, data center, and networking applications. The Lattice FPGA adds low latency, deterministic I/O alongside the NXP applications processor, delivering combined capabilities across real-time processing, AI, and custom I/O to help customers modernize aging designs for new interface standards. It supports e
FDA Approves PIMJETMI ® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor10.11.2026 20:14:00 EET | Press release
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. “People living with TGCT have long faced difficult treatment decisions as they navigate a disease that can significantly affect their daily lives including their mobility,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board for the Healthcare business of Merck. “Translating scientific innovation into clinically meaningful advances for people living with rare tumors is a strategic imperative for our company, as we continue our commitment to addressing significant unmet needs. With the approval of PIMJETMI in the U.S., we strengthen our leadership position and growing
Smartsheet Integrates With Claude Sheets, Making It Easy to Start Projects in Claude and Launch Workflows Across Teams with Smartsheet10.11.2026 19:57:00 EET | Press release
Smartsheet, the AI-powered enterprise work management platform, today announced a new integration with Claude Sheets, the new spreadsheet artifact in Claude from Anthropic, now in beta. With the new Send to Smartsheet feature, people who build a tracker or plan in Claude can move it into Smartsheet in a few clicks. There they can put it to work with their team, connected to the plans, projects, people and systems their organization already runs on. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110763156/en/ With the new Send to Smartsheet feature, people who build a tracker or plan in Claude can move it into Smartsheet in a few clicks. More and more work now begins in a conversation with Claude, and the Smartsheet MCP connector for Claude puts the entire power of the Smartsheet platform into play for users. Now with Claude Sheets, a person can think through a launch plan, a project tracker or a budget, and shape with the
InterSystems Joins Google Cloud as Launch Partner for Gemini for Healthcare10.11.2026 19:00:00 EET | Press release
InterSystems, a creative data technology provider powering more than one billion health records globally, today announced that it will serve as a launch partner for Google Cloud’s Gemini for healthcare. Through the collaboration, Gemini for healthcare will connect to the InterSystems IRIS FHIR Model Context Protocol (MCP) server, enabling healthcare organizations to give AI assistants and agents governed access to FHIR data. The integration will bring together Google Cloud’s Gemini capabilities and the standards-based data access provided by InterSystems IRIS FHIR MCP. InterSystems FHIR MCP serves the open Model Context Protocol directly from a FHIR endpoint, allowing MCP-enabled clients to discover and use FHIR tools for searching, reading, creating, updating, and managing healthcare data. “Healthcare organizations are looking for practical ways to apply AI to their data without compromising security, governance, or interoperability,” said Don Woodlock, president of InterSystems. “By
Coherent Solutions Launches AKTIV, a Dedicated Fitness and Wellness Technology Business Unit10.11.2026 17:34:00 EET | Press release
Coherent Solutions officially launches AKTIV, a dedicated business unit focused exclusively on fitness and wellness technology. AKTIV brings together over 15 years of fitness industry experience, dedicated leadership, and global engineering capabilities to help fitness and wellness operators and equipment manufacturers compete through technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110242555/en/ Coherent Solutions officially launches AKTIV “We know the fitness and wellness industry and the challenges operators and manufacturers face. With AKTIV, we spend less time defining what needs to be built and more time delivering solutions that improve operations, member experiences, and business performance,” said Vadim Bartlov, Managing Director of AKTIV. AKTIV builds on Coherent Solutions' established work with leading fitness companies, including Life Time, Planet Fitness, Anytime Fitness, Orangetheory, and BowFlex,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
